PPF ("PMG Partners Funds") - Helix Biotechnology Fund I

Dati di base

ISIN LU0426487442
Numero di valore 10173746
Bloomberg Global ID BBG000LZWTW4
Nome del fondo PPF ("PMG Partners Funds") - Helix Biotechnology Fund I
Offerente del fondo PMG Investment Solutions AG Zug, Schweiz
Telefono: +41 44 215 28 38
E-Mail: pmg@pmg.swiss
Web: https://www.pmg.swiss
Offerente del fondo PMG Investment Solutions AG
Rappresentante in Svizzera PMG Investment Solutions AG
Zug
Telefono: +41 44 215 28 38
Distributore(i) PMG Investment Solutions AG
Zug
Telefono: +41 44 215 28 38
Asset class Fondi azionari
EFC Categoria
Classe di quote Accumulation
Paese di domicilio Lussemburgo
Condizioni all-unknown-emissione Commissione di emissione a favore della direzione del fondo e/o del distributore (può variare per stesso fondo a seconda del canale di distribuzione)
Condizioni al riscatto Nessuna commissione di riscatto e/o altre commissioni a favore del fondo (riscatto al valore d’inventario)
Strategia d'investimenti *** The objective of the investment policy of the Subfund is to achieve the highest possible long-term capital growth in US dollars by taking advantage of the opportunities offered by biotech and pharmaceutical shares on the global stock markets. This involves investing in listed shares of companies that specialise in the identification, development and production of innovative chemical products for the healthcare sector. To achieve the investment objectives, the subfund will primarily invest in equities and, in part, in futures and exchange-traded options. The country-specific focus of the Fund is on the United States, Europe and the Asia region. This focus also includes investments in emerging markets in Europe and Asia. Investments are made in securities irrespective of their market capitalisation (small cap, mid cap, large cap). Up to 10% of the assets of the subfund may also be invested in China Connect Securities via the Stock Connect Programme.
Particolarità

Prezzi del fondo

Prezzo attuale * 85.62 USD 13.08.2025
Prezzo precedente * 82.96 USD 12.08.2025
Max 52 settimani * 95.45 USD 21.08.2024
Min 52 settimani * 73.04 USD 08.04.2025
NAV * 85.62 USD 13.08.2025
Issue Price *
Redemption Price *
Closing Price *
Prezzo minimo indicativo
Attivo del fondo *** 16'036'849
Attivo della classe *** 11'431'874
Trading Information SIX

Performance

Performance YTD +3.39% 31.12.2024
13.08.2025
Performance YTD (in CHF) -8.28% 31.12.2024
13.08.2025
1 mese +3.06% 14.07.2025
13.08.2025
3 mesi +13.12% 13.05.2025
13.08.2025
6 mesi -1.06% 13.02.2025
13.08.2025
1 anno -6.84% 13.08.2024
13.08.2025
2 anni +0.66% 14.08.2023
13.08.2025
3 anni -21.28% 16.08.2022
13.08.2025
5 anni -31.11% 13.08.2020
13.08.2025

Dati fiscali

Quota di partecipazione al capitale in %
Utile totale del fondo in %
Quota immobiliare in %
ADDI
ADDI Date

10 posizioni principali ***

Vertex Pharmaceuticals Inc 9.53%
Amgen Inc 8.43%
Gilead Sciences Inc 8.43%
Regeneron Pharmaceuticals Inc 7.05%
AstraZeneca PLC ADR 4.39%
Alnylam Pharmaceuticals Inc 3.56%
Royalty Pharma PLC Class A 2.33%
argenx SE ADR 2.32%
Biogen Inc 2.20%
Insmed Inc 2.06%
Ultimo aggiornamento dei dati 30.04.2025

Costi / Rischi

TER 2.29%
Data TER 31.12.2024
Performance Fee *** 20.00%
PTR
Max. Management Fee *** 1.20%
Ongoing Charges *** 1.75%
SRRI ***
Data SRRI *** 31.07.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price commissioni escluse, per fondi quotati in borsa NAV o quotazione di chiusura
** La calculazione del utile intermedio era fatto via § 9 Satz 2 InvStG
*** Sorgente dati: Morningstar (I dati si basano sulla posizione lunga riscalata delle partecipazioni)